Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab and Carbon-Ion Radiotherapy for Recurrent Nasopharyngeal Carcinoma
NCT04143984Phase 2Recruiting
- Sponsor
- Shanghai Proton and Heavy Ion Center
- Start
- Jan 2021
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in nasopharyngeal carcinoma (NPC), sponsored by Shanghai Proton and Heavy Ion Center. Started Jan 2021; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT04143984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04143984.